Fly News Breaks for January 28, 2020
Jan 28, 2020 | 07:28 EDT
Credit Suisse analyst Martin Auster raised his price target for Acceleron to $99 from $58 following "positive" sotatercept PULSAR PAH Phase 2 results. The analyst argues that positive development of sotatercept provides two sources of value, namely provides Acceleron with its first wholly owned late-stage asset, expanding the story beyond the prevailing consensus of being "just a luspatercept royalty stream," and elevates the company's M&A attractiveness. Auster has an Outperform rating on the shares.
News For XLRN From the Last 2 Days
There are no results for your query XLRN